Physician profile
Thomas Kalkiewicz, JR.
NPI 1255490512
$2,622.54
in general payments reported to CMS, 2019-2025
21 companies · $917 in 2025
The $917 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $152 · 2021: $103 · 2022: $167 · 2023: $515 · 2024: $613 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $626.88 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $301.55 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $263.22 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Ironshore Pharmaceuticals INC. | $232.76 | 2022-2024 | Jornay Pm |
| Pfizer INC. | $207.19 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $141.29 | 2025 | Neffy |
| Tris Pharma INC | $133.26 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Merck Sharp & Dohme LLC | $112.02 | 2021-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Sanofi Pasteur INC. | $80.08 | 2020-2023 | |
| Seqirus USA INC | $78.69 | 2024-2025 | Flucelvax, Fluad |
| Kaleo, INC. | $68.34 | 2019-2024 | Auvi-Q |
| Adlon Therapeutics L.P. | $62.61 | 2019-2020 | |
| Cranial Technologies, INC | $58.32 | 2025 | Doc Band |
| Alk-Abello, INC | $56.49 | 2025 | Neffy |
| Alexion Pharmaceuticals, INC. | $40.96 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $37.78 | 2024-2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $35.52 | 2025 | Qelbree |
| Verrica Pharmaceuticals INC. | $30.28 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $26.98 | 2025 | Vpriv |
| Phadia US INC. | $16.96 | 2025 | Immunocap |
| Genentech USA, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kalkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.